Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - calcium carbonate, colecalciferol - tablets effervescent - 600 mg + 400 iu base milligrams - calcium, combinations with other drugs

United States - English - NLM (National Library of Medicine)

paddock laboratories, llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate tablets, usp are indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. patients with hypercalcemia.

United States - English - NLM (National Library of Medicine)

safecor health, llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate tablets, usp are indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. patients with hypercalcemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - calcium folinate pentahydrate 12.71 mg/ml equivalent to 10 mg/ml folinic acid - concentrate for injection - 10 mg/ml - active: calcium folinate pentahydrate 12.71 mg/ml equivalent to 10 mg/ml folinic acid excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - · as rescue therapy to reduce toxicity following high-dose methotrexate therapy. · has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions · overdosage of methotrexate and in impaired methotrexate elimination · reducing the toxicity and circumventing the effect of folic acid antagonists

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: titanium dioxide; povidone; magnesium stearate; microcrystalline cellulose; hypromellose; carnauba wax; macrogol 8000; chlorophyllin-copper complex; croscarmellose sodium; crospovidone - a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium,calcium carbonate,colecalciferol,microcrystalline cellulose -

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c: calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown.

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate tablets contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a c

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and d

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unk